May 1, 2025 10:55 AM EDT
Pharma
FDA+

FDA ap­proves Sat­suma's mi­graine nasal spray af­ter re­jec­tion in 2024

Max Gelman

Senior Editor

The FDA ap­proved a new nasal spray for mi­graines that was de­vel­oped by Sat­suma Phar­ma­ceu­ti­cals.

Pre­vi­ous­ly called STS101, the com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

US drug­mak­ers in­creas­ing­ly look abroad for clin­i­cal tri­als as con­fi­dence in FDA wa­vers

Lil­ly meets sales ex­pec­ta­tions, but No­vo gains on PBM win

Ex­clu­sive: Ex-Cal­i­co sci­en­tist launch­es State­ly Bio with new way to study cells

Af­ter hunt for al­ter­na­tives, Kro­nos Bio se­lects Tang Cap­i­tal's Con­cen­tra for a deal

Mod­er­na ex­pands ef­fort to rein in costs in an ‘un­cer­tain en­vi­ron­ment’

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times